AOD-9604 for fat loss: what the evidence actually shows
Quick answer
AOD-9604 is a synthetic peptide fragment of human growth hormone (amino acids 176-191) that showed lipolytic activity in animal models without significantly affecting insulin sensitivity or IGF-1 levels. Phase 2 and Phase 3 human clinical trials conducted by Metabolic Pharmaceuticals failed to demonstrate statistically significant weight loss versus placebo, and the compound has no approved therapeutic indication for obesity in the US, EU, or Australia. Separate research threads are exploring its potential in cartilage repair, but this evidence base also remains largely preclinical.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @livvvvvk actually say?
Liv describes AOD-9604 as an "anti obesity drug" that works by "mimicking natural growth hormone to regulate your fat metabolism." She says it induces lipolysis, prevents future fat storage, and unlike semaglutide, leaves your appetite intact so you can still build muscle. She ends with a discount code and a link to buy.
To her credit, she's accurate on the abbreviation: AOD does stand for anti-obesity drug, and the compound is a synthetic fragment of human growth hormone (hGH), specifically amino acids 176-191. The mechanism description, lipolysis promotion, is grounded in real preclinical data. But the leap from "this works in rats" to "go use my discount code" skips several important steps, including the fact that AOD-9604 failed its pivotal human trials and was never approved by any major regulatory agency for weight loss.
Does the science back this up?
The preclinical data is genuinely interesting, but human evidence is thin. The compound showed promise in animal models, but clinical trials in humans did not replicate those results at a meaningful scale.
AOD-9604 was developed by Metabolic Pharmaceuticals in the early 2000s. In obese mouse models, it did demonstrate lipolytic activity without the hyperglycemic effects associated with full-length hGH (Heffernan et al., 2001, Journal of Endocrinology). That part, Liv gets basically right. The compound does appear to work through beta-3 adrenergic receptors to stimulate fat breakdown, and it does not appear to significantly affect insulin sensitivity in those models.
However, Phase 2 and Phase 3 human clinical trials (METRO studies, Metabolic Pharmaceuticals, 2004-2007) failed to show statistically significant weight loss compared to placebo. The compound was not approved by the FDA or TGA for obesity treatment. It currently has no approved therapeutic use for weight loss in any major jurisdiction. The cartilage regeneration angle is a separate research thread, still largely preclinical.
What did they get wrong (or right)?
Liv gets the mechanism description mostly right and deserves credit for not overstating the insulin sensitivity angle, which is actually one of the more supported claims about AOD-9604. But she makes a critical error of omission: she never mentions the drug failed human trials.
She also says it "induces lipogenesis" which is the opposite of what she means. Lipogenesis is fat creation. She likely meant lipolysis inhibition or anti-lipogenesis. This is a meaningful factual error, not a small one. Lipogenesis and lipolysis are opposing metabolic processes.
The comparison to semaglutide is also misleading. Semaglutide has extensive Phase 3 data showing 15-17% body weight reduction in clinical trials (Wilding et al., 2021, New England Journal of Medicine). AOD-9604 has no comparable human evidence. Framing these as comparable alternatives, where AOD is just the version that lets you keep your appetite, misrepresents the evidence gap between them significantly.
- Got right: AOD-9604 does appear to mimic the lipolytic fragment of hGH
- Got right: It does not appear to strongly affect insulin sensitivity in preclinical models
- Got wrong: Called it something that "induces lipogenesis" when she meant the opposite
- Got wrong: Never disclosed that human trials failed to show significant weight loss
- Problematic: Ends with a purchase link and discount code for an unapproved compound
What should you actually know?
AOD-9604 is not approved by the FDA for any indication. It is not a drug you can get prescribed for weight loss through standard medical channels in the US. That does not mean no one uses it, but it means the safety and efficacy data in humans is far weaker than this video implies.
The compound has an interesting safety profile in the sense that it does not appear to cause the blood sugar dysregulation associated with full hGH. That is genuinely worth noting. But "does not cause one bad thing" is not the same as "is proven to work and is safe long-term." Long-term human safety data does not exist in any robust form.
If you are cutting and want to preserve muscle while losing fat, that is a legitimate goal. There are compounds with actual human trial data behind them. AOD-9604 is not currently one of them. Anyone selling it with a discount code and no mention of its regulatory status or failed trials is not giving you the full picture. A regulated telehealth provider should be your first conversation, not a TikTok bio link.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For AOD-9604 for fat loss: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
AOD-9604 for fat loss: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
AOD-9604 is a synthetic peptide fragment of human growth hormone (amino acids 176-191) that showed lipolytic activity in animal models without significantly affecting insulin sensitivity or IGF-1 levels.
FormBlends verdict
AOD-9604 is a synthetic peptide fragment of human growth hormone (amino acids 176-191) that showed lipolytic activity in animal models without significantly affecting insulin sensitivity or IGF-1 levels. Phase 2 and Phase 3 human clinical trials conducted by Metabolic Pharmaceuticals failed to demonstrate statistically significant weight loss versus placebo, and the compound has no approved therapeutic indication for obesity in the US, EU, or Australia. Separate research threads are exploring its potential in cartilage repair, but this evidence base also remains largely preclinical.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- AOD-9604 is a synthetic peptide fragment of human growth hormone (amino acids 176-191) that showed lipolytic activity in animal models without significantly affecting insulin sensitivity or IGF-1 levels. Phase 2 and Phase 3 human clinical trials conducted by Metabolic Pharmaceuticals failed to demonstrate statistically significant weight loss versus placebo, and the compound has no approved therapeutic indication for obesity in the US, EU, or Australia. Separate research threads are exploring its potential in cartilage repair, but this evidence base also remains largely preclinical.
- AOD-9604 failed Phase 3 human clinical trials for weight loss and is not approved by the FDA, TGA, or EMA for any obesity indication.
- Preclinical studies (Ng et al., 2000, Molecular and Cellular Endocrinology) show real lipolytic activity in rodent models, but animal results have not translated to significant human weight loss in trials.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- AOD-9604 failed Phase 3 human clinical trials for weight loss and is not approved by the FDA, TGA, or EMA for any obesity indication.
- Preclinical studies (Ng et al., 2000, Molecular and Cellular Endocrinology) show real lipolytic activity in rodent models, but animal results have not translated to significant human weight loss in trials.
- The creator confused lipogenesis (fat creation) with lipolysis inhibition (preventing fat storage), which are opposite processes. This is a material factual error.
- AOD-9604 does appear to spare insulin sensitivity and IGF-1 elevation compared to full hGH, which is one of its genuinely supported pharmacological properties in preclinical data.
- Semaglutide and AOD-9604 are not comparable alternatives. Semaglutide has robust Phase 3 data; AOD-9604 does not. Presenting them as competing options misrepresents the evidence gap.
- Purchasing peptides via TikTok bio links with discount codes bypasses any medical supervision and quality control. Compounded peptides vary significantly in purity and concentration across unregulated vendors.
- Cartilage regeneration research for AOD-9604 exists but is largely preclinical. No approved therapeutic indication exists in this area either.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
livvvvvk · TikTok creator
217.8K views on this video
AOD-9604 Fat loss peptide (anti obesity drug) Mimics natural growth hormone in regulating fat metabolism without the adverse effefcts on insulin sensitivity Promotes breakdown of fat in the body Lipogenesis inhibition so it prevents future fat storage Helps with cartilage regeneration Does not effect muscle mass or blood sugar levels Benefits: weight loss, fat reduction is tough areas like the stomach, enhances metabolic rate, appetite regulation, cardiovascular health, improves mood, inc
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by livvvvvk, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.